The relationships of c Kit expression and mutations, and patients' response to imatinib-tailored therapy deserve further investigation in conjunction with clinical trials to gain deeper insight into pathways of c Kit regulation and signalling in breast cancer. This evidence concerns the gene KIT and breast cancer.